When does the Eliquis (apixaban) patent end?
Eliquis patent and exclusivity timing depends on which protection you mean: patents that cover different pieces of Eliquis (drug substance, formulations, and dosing), versus regulatory exclusivities that can delay generic or biosimilar competition even after a patent expires. The exact end date also varies by country.
What does DrugPatentWatch.com say about Eliquis patent expiry?
For up-to-date, jurisdiction-specific information on Eliquis patent status and expected expiry dates, DrugPatentWatch tracks the relevant patent filings and estimated timelines. You can check the Eliquis entry here: DrugPatentWatch - Eliquis.
Does the Eliquis “end” date differ by country?
Yes. Generic entry timing can change based on:
- Which patents are granted and in force in that country
- Whether exclusivities (regulatory protections) are still active
- Any patent litigation or settlements that affect launch timing
What’s usually the practical “end date” people mean?
Most people mean the first date a generic manufacturer can launch an apixaban product without violating active patent rights and after any applicable regulatory exclusivities end. That “launch eligibility” date is often later than a single patent’s expiration because multiple patents and legal protections can overlap.
Can more than one patent extend Eliquis beyond a single expiration date?
Yes. Eliquis can have multiple overlapping patents (for example, on certain formulations or specific claims). Even if one patent ends, others can still block a generic launch until they expire or are otherwise cleared.
What I need from you to give a specific date
Eliquis patent “end” can’t be pinned to one universal day. Tell me:
1) Which country (US, UK, EU, Canada, etc.), and
2) Whether you mean “patent expiry” or “earliest generic launch,”
and I can narrow it to the relevant dates using the DrugPatentWatch record.
Sources
- https://www.drugpatentwatch.com/